{
    "2018-04-13": [
        [
            {
                "time": "2018-04-09",
                "original_text": "Pharma Stock Roundup: NVS to Buy AveXis, PFE & ABBV's Drugs Succeed in Phase III",
                "features": {
                    "keywords": [
                        "NVS",
                        "AveXis",
                        "PFE",
                        "ABBV",
                        "Phase III"
                    ],
                    "sentiment_score": 0.75,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-04-10",
                "original_text": "Bristol-Myers Collaborates With Harvard Fibrosis Network",
                "features": {
                    "keywords": [
                        "Bristol-Myers",
                        "Harvard",
                        "Fibrosis",
                        "Collaboration"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-04-11",
                "original_text": "Rigel Pharmaceuticals' (RIGL) Stock Gains 16%: Here's Why",
                "features": {
                    "keywords": [
                        "Rigel",
                        "Pharmaceuticals",
                        "Stock Gains",
                        "RIGL"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-04-12",
                "original_text": "Gene Therapy in Limelight on Novartis Deal: 3 Stocks in Focus",
                "features": {
                    "keywords": [
                        "Gene Therapy",
                        "Novartis",
                        "Deal",
                        "Stocks in Focus"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "biotechnology"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-04-13",
                "original_text": "Glaxo to Sell Rare Disease Gene Therapies to Private Biotech",
                "features": {
                    "keywords": [
                        "Glaxo",
                        "Rare Disease",
                        "Gene Therapies",
                        "Private Biotech"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-04-14",
                "original_text": "The Swiss Stock Market Finished Nearly Unchanged In Choppy Trade",
                "features": {
                    "keywords": [
                        "Swiss Stock Market",
                        "Unchanged",
                        "Choppy Trade"
                    ],
                    "sentiment_score": 0.2,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "market"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-04-15",
                "original_text": "These 3 Biotech Stocks Are Up More Than 500% Over the Last 3 Years",
                "features": {
                    "keywords": [
                        "Biotech Stocks",
                        "Up More Than 500%"
                    ],
                    "sentiment_score": 0.95,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "biotechnology"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-04-16",
                "original_text": "Same as the old boss â€” Novan makes interim CEO permanent",
                "features": {
                    "keywords": [
                        "Novan",
                        "interim CEO",
                        "permanent"
                    ],
                    "sentiment_score": 0.4,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "management"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            }
        ]
    ]
}